Regenxbio announced on May 14, 2026 that its experimental gene therapy for Duchenne muscular dystrophy succeeded in clinical trials, producing sufficiently high levels of a miniaturized muscle protein and enabling FDA submission for accelerated approval. The company is positioning its therapy as safer and more effective than Sarepta Therapeutics' Elevidys, which has been hampered by safety concerns including two deaths from liver failure.
Duchenne gene therapy trial results
- ▪Regenxbio's experimental gene therapy for Duchenne muscular dystrophy produced sufficiently high levels of a miniaturized muscle protein broken in the fatal neuromuscular disease
- ▪Regenxbio announced the Duchenne gene therapy trial results on May 14, 2026
FDA submission plans
- ▪Regenxbio's Duchenne gene therapy trial results are paving the way for a submission to the Food and Drug Administration
- ▪Regenxbio's headquarters is located in Rockville, Maryland
- ▪Regenxbio CEO Curran Simpson stated that Regenxbio's data checks every single box needed for accelerated approval
- ▪Curran Simpson is the CEO of Regenxbio
Comparison to Sarepta's Elevidys
- ▪Regenxbio is seeking to create a Duchenne gene therapy that is more effective than Sarepta Therapeutics' Elevidys
Elevidys safety concerns
- ▪Sarepta Therapeutics' Elevidys has been hampered by safety concerns
- ▪Two recipients of Sarepta Therapeutics' Elevidys died from liver failure
Perspective of Sarepta Therapeutics
- ▪Regenxbio is positioning its Duchenne gene therapy as a safer and more effective alternative to Sarepta Therapeutics' Elevidys
- ▪Sarepta Therapeutics' Elevidys has been hampered by safety concerns including two deaths from liver failure
Story comments
Loading comments…